These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9680099)

  • 21. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
    Mülder HS; Dekker H; Pinedo HM; Lankelma J
    Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes.
    Vergote J; Moretti JL; de Vries EG; Garnier-Suillerot A
    Eur J Biochem; 1998 Feb; 252(1):140-6. PubMed ID: 9523723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
    Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
    Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological activities of a 3'-azido analogue of Doxorubicin against drug-resistant cancer cells.
    Yu S; Zhang G; Zhang W; Luo H; Qiu L; Liu Q; Sun D; Wang PG; Wang F
    Int J Mol Sci; 2012; 13(3):3671-3684. PubMed ID: 22489175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of multidrug resistance in breast cancer cells by a combination of ursolic acid with doxorubicin.
    Zong L; Cheng G; Liu S; Pi Z; Liu Z; Song F
    J Pharm Biomed Anal; 2019 Feb; 165():268-275. PubMed ID: 30572191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
    Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
    Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolation and characterization of daunorubicin-resistant AML-2 sublines.
    Choi CH; Ling V
    Mol Cells; 1997 Apr; 7(2):170-7. PubMed ID: 9163728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monensin and verapamil do not alter intracellular localisation of daunorubicin in multidrug resistant human KB cells.
    Wood DJ; Rumsby MG; Warr JR
    Cancer Lett; 1996 Nov; 108(1):41-7. PubMed ID: 8950207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression.
    Coley HM; Workman P; Twentyman PR
    Br J Cancer; 1991 Mar; 63(3):351-7. PubMed ID: 1672252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of competition of substrates for P-glycoprotein in MCF-7 breast cancer cells overexpressing MDR1.
    Hall JG; Cory AH; Cory JG
    Adv Enzyme Regul; 1999; 39():113-28. PubMed ID: 10470369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine.
    Shiraki N; Hamada A; Ohmura T; Tokunaga J; Oyama N; Nakano M
    Biol Pharm Bull; 2001 May; 24(5):555-7. PubMed ID: 11379779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells.
    Nagasawa K; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
    Biol Pharm Bull; 1996 Jul; 19(7):971-6. PubMed ID: 8839972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine.
    Fujita R; Ishikawa M; Takayanagi M; Takayanagi Y; Sasaki K
    Methods Find Exp Clin Pharmacol; 2000 Jun; 22(5):281-4. PubMed ID: 11031728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity.
    Jonsson O; Behnam-Motlagh P; Persson M; Henriksson R; Grankvist K
    Biochem Pharmacol; 1999 Dec; 58(11):1801-6. PubMed ID: 10571255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential expression and activity of P-glycoprotein and multidrug resistance-associated protein in CD34-positive KG1a leukemic cells.
    Fardel O; Payen L; Courtois A; Drenou B; Fauchet R; Rault B
    Int J Oncol; 1998 Feb; 12(2):315-9. PubMed ID: 9458355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes.
    Hurwitz SJ; Terashima M; Mizunuma N; Slapak CA
    Blood; 1997 May; 89(10):3745-54. PubMed ID: 9160680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.
    Bennis S; Faure P; Chapey C; Hu YP; Fourche J; El Yamani J; Robert J
    Anticancer Drugs; 1997 Jul; 8(6):610-7. PubMed ID: 9300576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.
    Dale IL; Tuffley W; Callaghan R; Holmes JA; Martin K; Luscombe M; Mistry P; Ryder H; Stewart AJ; Charlton P; Twentyman PR; Bevan P
    Br J Cancer; 1998 Oct; 78(7):885-92. PubMed ID: 9764579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.
    Gupta S; Patel K; Singh H; Gollapudi S
    Cancer Lett; 1994 Jan; 76(2-3):139-45. PubMed ID: 7511983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modification by brefeldin A, bafilomycin A1 and 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD) of cellular accumulation and intracellular distribution of anthracyclines in the non-P-glycoprotein-mediated multidrug-resistant cell line COR-L23/R.
    Rhodes T; Barrand MA; Twentyman PR
    Br J Cancer; 1994 Jul; 70(1):60-6. PubMed ID: 7912544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.